PE20181503A1 - Nuevos derivados de fosfinanos y azafosfinanos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen - Google Patents
Nuevos derivados de fosfinanos y azafosfinanos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienenInfo
- Publication number
- PE20181503A1 PE20181503A1 PE2018001210A PE2018001210A PE20181503A1 PE 20181503 A1 PE20181503 A1 PE 20181503A1 PE 2018001210 A PE2018001210 A PE 2018001210A PE 2018001210 A PE2018001210 A PE 2018001210A PE 20181503 A1 PE20181503 A1 PE 20181503A1
- Authority
- PE
- Peru
- Prior art keywords
- phosphinans
- apshosphines
- pharmaceutical compositions
- compositions containing
- preparation procedure
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 230000007213 cerebrovascular event Effects 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 125000001153 fluoro group Chemical group F* 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical group CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 abstract 1
- 230000002685 pulmonary effect Effects 0.000 abstract 1
- 230000001732 thrombotic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6568—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus atoms as the only ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
- C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
- C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
- C07F9/65842—Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
- C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
- C07F9/65842—Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring
- C07F9/65846—Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring the phosphorus atom being part of a six-membered ring which may be condensed with another ring system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Se refiere a compuestos de Formula (I) Donde AK1 representa una cadena alquilo C1-C6, X representa -(CH2)m-, -CH(R)-, -N(R)-, entre otros, y m es un numero del 1 al 4. R representa a un atomo de hidrogeno o un grupo alquilo, entre otros. R1 y R2 representan cada uno un atomo de hidrogeno, entre otros. R3 representa NH, Cy-Ak3-NH o piperidin-4-ilo , entre otros. R4 y R5 son un atomo de hidrogeno o fluor. Dichos compuestos son utilizados en el tratamiento y prevencion de los eventos tromboticos, cardiovasculares, pulmonares, cerebrovasculares, diabetes, hiperlipidemia, enfermedad de Alzheimer, entre otros. Entre los compuestos preferidos tenemos los siguientes: acido 2-(3-aminopropil)-1-hidroxi-1-oxo-1-fosfolano-2-carboxilico, trifluoroacetato; acido 2-(4-aminobutil)-1-hidroxi-1-oxo-1-fosfolano-2-carboxilico, trifluoroacetato; entre otros.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1670004A FR3046793B1 (fr) | 2016-01-14 | 2016-01-14 | Nouveaux derives de phosphinanes et azaphosphinanes, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20181503A1 true PE20181503A1 (es) | 2018-09-18 |
Family
ID=55752640
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2018001210A PE20181503A1 (es) | 2016-01-14 | 2017-01-13 | Nuevos derivados de fosfinanos y azafosfinanos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen |
Country Status (47)
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR3046793B1 (fr) * | 2016-01-14 | 2018-01-05 | Les Laboratoires Servier | Nouveaux derives de phosphinanes et azaphosphinanes, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI1311488T1 (sl) * | 2000-08-17 | 2010-01-29 | Pfizer Ltd | Substituirani imidazoli kot inhibitorji TAFIA |
| SE0103272D0 (sv) * | 2001-09-28 | 2001-09-28 | Astrazeneca Ab | Chemical compounds |
| AU2002249275A1 (en) * | 2002-03-08 | 2003-09-22 | Warner-Lambert Company Llc | Oxo azabicyclic compounds |
| US7420000B2 (en) * | 2003-09-10 | 2008-09-02 | University Of Southern California | Amino phosphonate and amino bis-phosphonate derivatives |
| US20050143349A1 (en) * | 2003-12-17 | 2005-06-30 | Quatrx Pharmaceuticals Co. | Phosphorus containing compounds useful for the regulation of LDL and Lp(a) levels |
| EP1874322A1 (en) * | 2005-04-18 | 2008-01-09 | Bayer Schering Pharma Aktiengesellschaft | Use of tafi inhibitors for enhanced myocardial reperfusion and facilitated pci |
| ES2395581T3 (es) * | 2007-06-20 | 2013-02-13 | Merck Sharp & Dohme Corp. | Inhibidores de quinasas janus |
| FR2920773B1 (fr) * | 2007-09-11 | 2009-10-23 | Servier Lab | Derives de 1,2,4,5-tetrahydro-3h-benzazepines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| FR2947266B1 (fr) * | 2009-06-26 | 2011-06-17 | Servier Lab | Nouveaux derives d'acide 2-mercaptocyclopentanecarboxylique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| CA2771124C (en) * | 2009-09-09 | 2019-01-15 | Gilead Sciences, Inc. | Inhibitors of flaviviridae viruses |
| CA2872110C (en) * | 2012-07-18 | 2019-08-06 | Sunshine Lake Pharma Co., Ltd. | Nitrogenous heterocyclic derivatives and their application in drugs |
| FR3046793B1 (fr) * | 2016-01-14 | 2018-01-05 | Les Laboratoires Servier | Nouveaux derives de phosphinanes et azaphosphinanes, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
-
2016
- 2016-01-14 FR FR1670004A patent/FR3046793B1/fr not_active Expired - Fee Related
- 2016-12-27 JO JOP/2016/0275A patent/JO3660B1/ar active
-
2017
- 2017-01-11 UY UY0001037072A patent/UY37072A/es unknown
- 2017-01-12 AR ARP170100074A patent/AR107433A1/es unknown
- 2017-01-12 TW TW106100930A patent/TWI625334B/zh not_active IP Right Cessation
- 2017-01-13 CN CN201780008078.XA patent/CN108495857A/zh active Pending
- 2017-01-13 ES ES17706525T patent/ES2709376T3/es active Active
- 2017-01-13 SG SG11201805757WA patent/SG11201805757WA/en unknown
- 2017-01-13 JP JP2018536455A patent/JP2019504070A/ja active Pending
- 2017-01-13 LT LTEP17706525.7T patent/LT3271368T/lt unknown
- 2017-01-13 WO PCT/FR2017/050075 patent/WO2017121969A1/fr active Application Filing
- 2017-01-13 BR BR112018014020-1A patent/BR112018014020A2/pt not_active IP Right Cessation
- 2017-01-13 US US15/548,533 patent/US10138260B2/en not_active Expired - Fee Related
- 2017-01-13 MX MX2018008639A patent/MX367319B/es active IP Right Grant
- 2017-01-13 EA EA201891599A patent/EA035072B1/ru not_active IP Right Cessation
- 2017-01-13 PL PL17706525T patent/PL3271368T3/pl unknown
- 2017-01-13 GE GEAP201714853A patent/GEP20207092B/en unknown
- 2017-01-13 TR TR2018/20430T patent/TR201820430T4/tr unknown
- 2017-01-13 CA CA3011184A patent/CA3011184C/fr not_active Expired - Fee Related
- 2017-01-13 DK DK17706525.7T patent/DK3271368T3/da active
- 2017-01-13 RS RS20190105A patent/RS58338B1/sr unknown
- 2017-01-13 RU RU2018129027A patent/RU2729641C2/ru not_active IP Right Cessation
- 2017-01-13 SI SI201730013T patent/SI3271368T1/sl unknown
- 2017-01-13 PE PE2018001210A patent/PE20181503A1/es unknown
- 2017-01-13 HU HUE17706525A patent/HUE042924T2/hu unknown
- 2017-01-13 TN TNP/2018/000226A patent/TN2018000226A1/fr unknown
- 2017-01-13 PT PT17706525T patent/PT3271368T/pt unknown
- 2017-01-13 KR KR1020187023228A patent/KR20180101522A/ko active IP Right Grant
- 2017-01-13 AU AU2017207003A patent/AU2017207003B2/en not_active Expired - Fee Related
- 2017-01-13 CU CUP2018000072A patent/CU20180072A7/es unknown
- 2017-01-13 UA UAA201808634A patent/UA121275C2/uk unknown
- 2017-01-13 ME MEP-2019-23A patent/ME03305B/me unknown
- 2017-01-13 MA MA41798A patent/MA41798B1/fr unknown
- 2017-01-13 MD MDE20180097T patent/MD3271368T2/ro not_active IP Right Cessation
- 2017-01-13 EP EP17706525.7A patent/EP3271368B1/fr active Active
-
2018
- 2018-03-19 HK HK18103808.6A patent/HK1244283B/zh not_active IP Right Cessation
- 2018-06-26 PH PH12018501373A patent/PH12018501373A1/en unknown
- 2018-06-29 ZA ZA2018/04391A patent/ZA201804391B/en unknown
- 2018-07-04 IL IL260425A patent/IL260425B/en active IP Right Grant
- 2018-07-05 SV SV2018005721A patent/SV2018005721A/es unknown
- 2018-07-06 NI NI201800073A patent/NI201800073A/es unknown
- 2018-07-09 DO DO2018000165A patent/DOP2018000165A/es unknown
- 2018-07-09 CL CL2018001862A patent/CL2018001862A1/es unknown
- 2018-07-11 EC ECSENADI201851972A patent/ECSP18051972A/es unknown
- 2018-07-12 CO CONC2018/0007271A patent/CO2018007271A2/es unknown
- 2018-10-04 US US16/151,597 patent/US10654878B2/en not_active Expired - Fee Related
- 2018-12-10 CY CY20181101320T patent/CY1121154T1/el unknown
-
2019
- 2019-01-30 HR HRP20190193TT patent/HRP20190193T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR068055A1 (es) | Derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol su procedimiento de preparacion su aplicacion como medicamentos composiciones farmaceuticas y su utilizacion principalmente como inhibidores de met | |
| CL2019003239A1 (es) | Amidas de piridona deuteradas y profármacos de los mismos como moduladores de canales de sodio. | |
| PE20210050A1 (es) | Nuevos compuestos de sulfonamida carboxamida | |
| ECSP078064A (es) | NUEVOS DERIVADOS de 2,4-DIANILINOPIRIMIDINAS, SU PREPARACIÓN, COMO MEDICAMENTOS, COMPOSICIONES FARMACÉUTICAS Y PRINCIPALMENTE COMO INHIBIDORES DE IKK | |
| AR037534A1 (es) | Derivado de adamantano, su uso en la fabricacion de un medicamento para usar en terapia, composicion farmaceutica, proceso para la preparacion de dicho compuesto y dicha composicion y compuestos intermediarios | |
| CL2014003181A1 (es) | Compuestos derivados de benzamidas n- sustituidas o piridinamidas n-sustituidas; composicion farmaceutica que los comprende; metodo de tratamiento; y su uso para el tratamiento de enfermedades o trastornos seleccionados de dolor, depresion y enfermedades cardiovasculares, respiratorias o psiquiatricas o combinaciones de estas. | |
| PE20170127A1 (es) | Indazol-3-carboxamidas 5-sustituidas y preparacion y uso de las mismas | |
| AR078152A1 (es) | Compuestos heterociclicos, utiles para el tratamiento de hcv y composiciones farmaceuticas que los comprenden | |
| UY29827A1 (es) | 2-amina-pirimidina-4-(2-metil-1-(tetrahidro-2h-piran-4-il)-1-imidazol-5-y1) sustituidas y sus derivados, composiciones farmacéuticas que las contienen, procesos para su preparación y aplicaciones | |
| PE20090620A1 (es) | Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen | |
| AR067927A1 (es) | Quinolinas sustituidas, composiciones y combinaciones que las comprenden y el uso de las mismas en la preparacion de un medicamento para tratamiento de enfermedades inflamatorias y/o alergicas del tracto respiratorio. | |
| AR051349A1 (es) | Compuestos de 4-carboxi pirazol, formulacion farmaceutica que los comprende y procesos de preparacion del mismo. | |
| AR043444A1 (es) | Profarmacos de diaril-2- 5h -furanonas que liberan oxido nitrico como inhibidores de la ciclooxigenasa-2 | |
| RU2017117559A (ru) | Бензопроизводные с шестичленным кольцом в качестве ингибитора dpp-4 и их применение | |
| AR045156A1 (es) | Derivados de 5-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos | |
| AR118983A1 (es) | Antagonistas cíclicos del receptor b2 de bradiquinina | |
| AR056528A1 (es) | Derivados de bencimidazoles y benzotiazoles su proceso de preparacion su aplicacion como medicamentos composiciones farmaceuticas y utilizacion principalmente como inhibidores de cmet | |
| PE20181503A1 (es) | Nuevos derivados de fosfinanos y azafosfinanos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| PE20181328A1 (es) | Compuestos de dihidroquinolinsulfonamida de alquilo | |
| CO6420339A2 (es) | Derivados de 6-(6-sustituido-triazolopiridacina-sulfanil) 5-fluoro-benzotiazoles y 5-fluoro-bencimidazoles : preparación, aplicación como medicamentos y utilización como inhibidores de met | |
| AR075250A1 (es) | Derivados de 6-(triazolopiridazinsulfanil sustituido en 6-nh)benzotiazoles y bencimidazoles; preparacion, aplicacion como medicamentos y utilizacion como inhibidores de met. | |
| AR058208A1 (es) | Derivados de indolizina,proceso de preparacion,composiciones farmaceuticas que los contienen y usos terapeuticos en alteraciones cardiovasculares. | |
| PE20211454A1 (es) | Derivados de imidazopiridina y su uso como medicamento | |
| EA202192111A1 (ru) | Новые тритерпеновые производные в качестве ингибиторов вич | |
| AR045158A1 (es) | Derivados de 7-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos |